EHDEN Network Open Call Process results – MediSapiens is selected in the first group of participating SMEs!
We’re honored to join the European Health Data & Evidence Network (EHDEN) which is an Innovative Medicines Initiative 2 (IMI2) consortium that brings 22 partners from across 12 countries together to develop a federated network, standardized to a common data model (CDM), the OMOP format. The EHDEN project aims to create a thriving ecosystem of data sources for federated analyses and of SMEs (Small & Medium-sized Enterprises) who help them map this data into the OMOP format.
The EHDEN consortium is evenly divided between eleven public partners, led by the Erasmus University Medical Centre, The Netherlands, and eleven pharmaceutical partners, led by Janssen Pharmaceutical Nv, Belgium.
EHDEN made its first open call to SMEs to apply for training and certification for the OMOP common data model earlier this year, after which eleven SMEs have been selected from a pool of twenty-eight eligible applications. We are happy and proud to announce that MediSapiens is chosen as one of the 11 participating SMEs. MediSapiens is looking forward to being a key part of the EHDEN community and to contribute to helping improve healthcare systems, and ultimately patient outcomes by utilizing transformational potential of real-world data (RWD).
“Being selected by the EHDEN consortium to receive training in the OMOP common data model as one of the first SMEs in Europe is a great honor”, Hans Garritzen, Sales Director at MediSapiens, says, “it is a natural next step for us to further develop our data standardization capabilities, after the earlier release of our curation technology Accurate™ and the data work we perform with our partners in pharma, biobanking and population-scale research and we are thus very motivated to join the EHDEN SME program.”
We look forward to the training and work with our partners to implement the OMOP Common Data Model!
For more information, please visit the EHDEN website.
The European Health Data & Evidence Network has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 806968. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.